title: Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei Infection, 2010.
abstract: The US Public Health Emergency Medical Countermeasures Enterprise convened subject matter experts at the 2010 HHS Burkholderia Workshop to develop consensus recommendations for postexposure prophylaxis against and treatment for Burkholderia pseudomallei and B. mallei infections, which cause melioidosis and glanders, respectively. Drugs recommended by consensus of the participants are ceftazidime or meropenem for initial intensive therapy, and trimethoprim/sulfamethoxazole or amoxicillin/clavulanic acid for eradication therapy. For postexposure prophylaxis, recommended drugs are trimethoprim/sulfamethoxazole or co-amoxiclav. To improve the timely diagnosis of melioidosis and glanders, further development and wide distribution of rapid diagnostic assays were also recommended. Standardized animal models and B. pseudomallei strains are needed for further development of therapeutic options. Training for laboratory technicians and physicians would facilitate better diagnosis and treatment options.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Lipsitz
authors.forename: Susan
authors.initials: S
authors.lastname: Garges
authors.forename: Rosemarie
authors.initials: R
authors.lastname: Aurigemma
authors.forename: Prasith
authors.initials: P
authors.lastname: Baccam
authors.forename: David D
authors.initials: DD
authors.lastname: Blaney
authors.forename: Allen C
authors.initials: AC
authors.lastname: Cheng
authors.forename: Bart J
authors.initials: BJ
authors.lastname: Currie
authors.forename: David
authors.initials: D
authors.lastname: Dance
authors.forename: Jay E
authors.initials: JE
authors.lastname: Gee
authors.forename: Joseph
authors.initials: J
authors.lastname: Larsen
authors.forename: Direk
authors.initials: D
authors.lastname: Limmathurotsakul
authors.forename: Meredith G
authors.initials: MG
authors.lastname: Morrow
authors.forename: Robert
authors.initials: R
authors.lastname: Norton
authors.forename: Elizabeth
authors.initials: E
authors.lastname: O'Mara
authors.forename: Sharon J
authors.initials: SJ
authors.lastname: Peacock
authors.forename: Nicki
authors.initials: N
authors.lastname: Pesik
authors.forename: L Paige
authors.initials: LP
authors.lastname: Rogers
authors.forename: Herbert P
authors.initials: HP
authors.lastname: Schweizer
authors.forename: Ivo
authors.initials: I
authors.lastname: Steinmetz
authors.forename: Gladys
authors.initials: G
authors.lastname: Tan
authors.forename: Patrick
authors.initials: P
authors.lastname: Tan
authors.forename: W Joost
authors.initials: WJ
authors.lastname: Wiersinga
authors.forename: Vanaporn
authors.initials: V
authors.lastname: Wuthiekanun
authors.forename: Theresa L
authors.initials: TL
authors.lastname: Smith
mesh_terms: D019980:Amoxicillin-Potassium Clavulanate Combination / Q000008:administration & dosage; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D042726:Burkholderia mallei / Q000472:pathogenicity*; D016957:Burkholderia pseudomallei / Q000472:pathogenicity*; D002442:Ceftazidime / Q000008:administration & dosage; D004195:Disease Models, Animal; D004198:Disease Susceptibility; D005896:Glanders / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D008554:Melioidosis / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control*; D000077731:Meropenem; D056990:Post-Exposure Prophylaxis / Q000379:methods*; D012307:Risk Factors; D013845:Thienamycins / Q000008:administration & dosage; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000008:administration & dosage
chemical_list: D000900:Anti-Bacterial Agents; D013845:Thienamycins; D019980:Amoxicillin-Potassium Clavulanate Combination; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D002442:Ceftazidime; D000077731:Meropenem